Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4

American Journal of Pathology

Volumn 160, Issue 3, 2002, Pages 1097-1103

  Griggs, Jeremy ^a   Skepper, Jeremy N ^a   Smith, Gerry A ^a   Brindle, Kevin M ^a   Metcalfe, James C ^a   Hesketh, Robin ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; COMBRETASTATIN A4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; TREATMENT OUTCOME;

EID: 0036120720     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64930-9     Document Type: Article

References (43)

1. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
2. Antiangiogenic strategies and agents in clinical trials
3. Angiogenesis in cancer and other diseases
4. Blindness caused by diabetic retinopathy
5. Retinal and choroidal neovascularization
6. Oxygen-induced retinopathy in the mouse
7. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
8. Vascular endothelial growth-factor vascular-permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model
9. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization
10. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy
11. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
12. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor
13. Targeting tumour vasculature: The development of combretastatin A4
14. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
15. Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4
16. Synthesis of biologically active polyphenolic glycosides (combretastatin and resveratrol series)
17. Antineoplastic agents-322-synthesis of combretastatin A-4 prodrugs
18. The balance between proteinases and inhibitors in a murine model of proliferative retinopathy
19. Dramatic inhibition of retinal and choroical neovascularization by oral administration of a kinase inhibitor
20. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization
21. Combretastatin A-4 phosphate an agent that displays potent and selective toxicity toward tumour neovasculature
22. Effects of combretastatin on murine tumours monitored by P-31 MRS, H-1 MRS and H-1 MRI
23. Combretastatin A-4 prodrug: A potent inhibitor of malignant hemangioendothelioma cell proliferation
24. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
25. Cembretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model
26. Potent anti-metastatic activity of combretastatin-A4
27. Therapeutic targeting of the tumour vasculature using the tubulin-binding agent combretastatin A4-P
28. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
29. Phase I pharmacokinetic and toxicity study of weekly intravenous combretastatin A4 phosphate (CA4P)
30. Phase I/pharmacokinetic trials of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily x 5 schedule every 21 days
31. Phase I pharmacokinetic study of single dose intravenous (IV) combretastatin A4 prodrug (CA4P) in patients (pts) with advanced cancer
32. A phase I pharmacokinetic (PK) study of single dose intravenous (IV) combretastatin A4 phosphate (CA4P) in patients (PTS) with advanced cancer final report
33. Measurement of tumour and normal (NT) perfusion by positron emission tomography (PET) in the evaluation of antivascular therapy: Results in the phase I study of combretastatin A4 phosphate (CA4P) Program Proceedings
34. Combretastatin A4 phosphate (CA4P) targets vasculature in animal and human tumours
35. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
36. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
37. Quantitative analysis of endothelial cell shape change after treatment with combretastatin A4 phosphate
38. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model
39. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization
40. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model
41. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
42. Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide